Lisa F Han, Ivis Perez, Kevin W McConeghy, David H Canaday, Elizabeth A Sillman, Clare Nugent, Tiffany Wallace, Laurel Holland, Evan Dickerson, Olajide Olagunju, Debbie Keresztesy, Yasin Abul, Stefan Gravenstein, H Edward Davidson
Respiratory virus surveillance varies widely between nursing homes (NHs) and is shaped by differences in staffing capacity, provider training, diagnostic resources, and facility-level protocols. CLIA-waived, point-of-care molecular testing devices were implemented as routine respiratory virus surveillance in 23 Medicare-certified U.S. NHs to evaluate feasibility.